Seizert Capital Partners LLC Has $4.19 Million Holdings in InMode Ltd. (NASDAQ:INMD)

Seizert Capital Partners LLC raised its position in shares of InMode Ltd. (NASDAQ:INMD - Free Report) by 105.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 250,627 shares of the healthcare company's stock after acquiring an additional 128,483 shares during the period. Seizert Capital Partners LLC owned approximately 0.30% of InMode worth $4,185,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Atria Investments Inc increased its position in InMode by 23.1% in the 4th quarter. Atria Investments Inc now owns 15,088 shares of the healthcare company's stock worth $252,000 after buying an additional 2,828 shares during the period. Marathon Asset Management Ltd increased its position in InMode by 57.4% during the fourth quarter. Marathon Asset Management Ltd now owns 182,349 shares of the healthcare company's stock worth $3,045,000 after acquiring an additional 66,475 shares during the period. SBI Securities Co. Ltd. acquired a new position in InMode during the 4th quarter valued at $87,000. Yelin Lapidot Holdings Management Ltd. boosted its holdings in InMode by 0.6% in the 4th quarter. Yelin Lapidot Holdings Management Ltd. now owns 308,852 shares of the healthcare company's stock valued at $5,158,000 after purchasing an additional 1,950 shares during the period. Finally, Atlas Legacy Advisors LLC acquired a new stake in InMode in the 4th quarter worth $848,000. 68.04% of the stock is owned by institutional investors and hedge funds.

InMode Price Performance

Shares of InMode stock traded down $0.29 during trading on Friday, hitting $19.02. 935,355 shares of the company's stock traded hands, compared to its average volume of 929,942. The company has a market cap of $1.32 billion, a PE ratio of 8.09 and a beta of 2.08. The firm's fifty day moving average price is $17.75 and its 200 day moving average price is $17.50. InMode Ltd. has a twelve month low of $14.87 and a twelve month high of $23.38.

Remove Ads

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Barclays upped their price objective on shares of InMode from $26.00 to $29.00 and gave the company an "overweight" rating in a research report on Wednesday, February 5th. Needham & Company LLC reaffirmed a "hold" rating on shares of InMode in a report on Tuesday, February 4th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $22.25.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.